Bolt's immune-stimulating antibody conjugates decrease tumor growth

Bolt said TLR agonist antibody conjugates from its Immune-Stimulating Antibody Conjugate (ISAC) platform led to immune activation and tumor clearance in preclinical cancer models.

In a presentation at the American Association for Cancer Research (AACR) meeting in Atlanta, Bolt Biotherapeutics Inc. (Redwood City, Calif.) described preclinical studies of antibody conjugates that comprise a TLR7/TLR8 agonist conjugated to tumor-targeting mAbs. In human cancer cell lines and leukocytes, the antibody conjugates activated antigen-presenting cells, increased expression of co-stimulatory molecules and pro-inflammatory cytokines, and induced dendritic cell differentiation from monocytes...